910629-24-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is used as an intermediate for the synthesis of various pharmaceuticals and natural products. Its unique structure and functional groups make it a valuable building block in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is used as a key component in the synthesis of complex organic molecules. Its versatile reactivity allows for the creation of a wide range of compounds with potential applications in drug discovery and development.
Used in Natural Product Synthesis:
(R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol is also employed in the synthesis of natural products, which are often sought after for their biological activities and potential use in the pharmaceutical industry. Its chiral nature and functional groups enable the creation of diverse natural product analogs with potential therapeutic properties.

Upstream product

• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 639468-72-7 phenyl(tetrahydro-2H-pyran-4-yl)methanone 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 100-52-7 benzaldehyde 
• 216087-92-2 rac-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 100-58-3 phenylmagnesium bromide 
• 3174-74-1 dihydropyran 
• 100-59-4 phenylmagnesium chloride 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 

Downstream Products

• 1800340-40-2 (-)-(S)-2-[3-(dimethyl-1H-1, 2,3-triazo1-5-yl)-5-[oxan-4-yl(phenyl)-methyl]-5H-pyrido [3,2-b] indol-7-yl]propan-2-ol 

Relevant academic research and scientific papers

Development of BET inhibitors as potential treatments for cancer: A search for structural diversity

We describe our efforts to identify structurally diverse leads in the triazole-containing N1-carboline series of bromodomain and extra-terminal inhibitors. Replacement of the N5 “cap” phenyl moiety with various heteroaryls, coupled with additional modifications to the carboline core, provided analogs with similar potency, improved pharmacokinetic properties, and increased solubility compared to our backup lead, BMS-986225 (2). Rapid SAR exploration was enabled by a convergent, synthetic route. These efforts provided a potent BET inhibitor, 3-fluoropyridyl 12, that demonstrated robust efficacy in a multiple myeloma mouse tumor model at 1 mg/kg.

Reductive Arylation of Amides via a Nickel-Catalyzed Suzuki–Miyaura-Coupling and Transfer-Hydrogenation Cascade

We report a means to achieve the addition of two disparate nucleophiles to the amide carbonyl carbon in a single operational step. Our method takes advantage of non-precious-metal catalysis and allows for the facile conversion of amides to chiral alcohols via a one-pot Suzuki–Miyaura cross-coupling/transfer-hydrogenation process. This study is anticipated to promote the development of new transformations that allow for the conversion of carboxylic acid derivatives to functional groups bearing stereogenic centers via cascade processes.

SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF

Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Manganese complex and preparation method and application thereof

The invention discloses a manganese complex taking (RC,SP)-N-5,6,7,8-tetrahydroquinoline-1-(2-diphenylphosphino)ferrocene ethyl amine as a ligand, a preparation method and application of the manganesecomplex in catalyst ketone compound asymmetric hydrogen transfer reduction preparing chiral alcohol. The manganese complex is a cheap metal chiral catalyst, the cost is low, the thermal stability isgood, and the preparation method of the manganese complex has the advantages of mild condition, short period, simple operation condition and the like. The catalyst is used for reducing the chiral alcohol for ketone hydrogen transfer, has higher catalytic activity, and a method for preparing the chiral alcohol is simple, less in environment pollution, and high in yield.

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

Aromatic-ring-containing compound, preparation method thereof, pharmaceutical composition and application thereof

The invention discloses an aromatic-ring-containing compound, a preparation method thereof, a pharmaceutical composition and application. The present invention provides the aromatic-ring-containing compound represented by a formula 1, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or a solvate thereof, and the aromatic-ring-containing compound can be effectively bounded to bromodomains of BRD4, BRD3, BRD2, and BRDT in BET family to regulate transcription of downstream gene c-myc and related target genes of the c-myc so as to regulate downstream signalingpathways to play specific roles including treatment of diseases such as inflammatory diseases, cancer, and AIDS. Some of the compounds have high activity, and have good cell activity and metabolic stability, so that the compounds can be an effective drug for treating tumors.

Branch-Selective Addition of Unactivated Olefins into Imines and Aldehydes

Radical hydrofunctionalization occurs with ease using metal-hydride hydrogen atom transfer (MHAT) catalysis to couple alkenes and competent radicalophilic electrophiles. Traditional two-electron electrophiles have remained unreactive. Herein we report the reductive coupling of electronically unbiased olefins with imines and aldehydes. Iron catalysis allows addition of alkyl-substituted olefins into imines through the intermediacy of free radicals, whereas a combination of catalytic Co(Salt-Bu,t-Bu) and chromium salts enables a branch-selective coupling of olefins and aldehydes through the formation of a putative alkyl chromium intermediate.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The "reverse-tethered" ruthenium (II) catalyst for asymmetric transfer hydrogenation: Further applications

The attachment of a tethering group from the basic nitrogen atom to the arene ligand of a ruthenium(II) catalyst greatly improves its ability to catalyze asymmetric transfer hydrogenation (ATH) reactions. In this paper, we describe further applications of this versatile system to an extended substrate range.